|
End-of-day quote
Other stock markets
|
5-day change | 1st Jan Change | ||
| 20.40 CNY | -0.78% |
|
+0.29% | +8.17% |
| Capitalization | 8.44B 1.21B 1.03B 955M 896M 1.67B 111B 1.77B 10.9B 4.32B 52.44B 4.54B 4.44B 192B | P/E ratio 2025 * |
10.8x | P/E ratio 2026 * | 7.11x |
|---|---|---|---|---|---|
| Enterprise value | 8.44B 1.21B 1.03B 955M 896M 1.67B 111B 1.77B 10.9B 4.32B 52.44B 4.54B 4.44B 192B | EV / Sales 2025 * |
-
| EV / Sales 2026 * | - |
| Free-Float |
22.45% | Yield 2025 * |
0.93% | Yield 2026 * | - |
More valuation ratios
* Estimated data
More news
| 1 day | -0.78% | ||
| 1 week | +0.29% | ||
| Current month | +8.17% | ||
| 1 month | +5.64% | ||
| 3 months | -8.23% | ||
| 6 months | -9.73% | ||
| Current year | +8.17% |
| 1 week | 19.73 |  | 20.98 |
| 1 month | 18.83 | | 20.98 |
| Current year | 18.85 | | 20.98 |
| 1 year | 18.83 | | 26.3 |
| 3 years | 18.83 | | 74.99 |
| 5 years | 18.83 | | 135.88 |
| 10 years | 18.83 | | 135.88 |
| Manager | Title | Age | Since |
|---|---|---|---|
Wei Kong
CEO | Chief Executive Officer | 61 | 2003-12-31 |
Zhao Feng Meng
DFI | Director of Finance/CFO | 62 | 2019-01-31 |
Chang Lin Zhu
CTO | Chief Tech/Sci/R&D Officer | 58 | 2003-12-31 |
| Director | Title | Age | Since |
|---|---|---|---|
Xiu Feng Li
BRD | Director/Board Member | 57 | 2004-02-29 |
Xing Gong Zhu
BRD | Director/Board Member | 59 | 2021-08-02 |
De Shen Zhang
BRD | Director/Board Member | 62 | 2019-02-20 |
| Change | 5d. change | 1-year change | 3-years change | Capi.($) | ||
|---|---|---|---|---|---|---|
 | -0.78% | +0.29% | -10.96% | -72.43% | 1.22B | |
| +3.46% | +1.10% | -11.02% | -31.48% | 63.11B | |
| +0.52% | +1.32% | +14.12% | -8.74% | 8.58B | |
| -0.59% | -2.29% | +27.44% | +38.53% | 8.43B | |
| +1.93% | -4.28% | +7.89% | +62.06% | 6.1B | |
| +1.95% | -4.03% | -20.55% | +106.07% | 5.24B | |
| +1.70% | -0.27% | +174.24% | +36.90% | 4.12B | |
| -2.23% | -7.27% | -16.35% | -22.35% | 2.95B | |
| -5.27% | +3.58% | +53.39% | +43.35% | 2.93B | |
| -0.85% | -5.21% | +27.27% | +21.81% | 2.84B | |
| Average | -0.02% | -1.87% | +24.55% | +17.37% | 10.55B | |
| Weighted average by Cap. | +2.10% | -2.07% | +4.62% | -5.84% |
| 2025 * | 2026 * | |
|---|---|---|
| Net sales | - | - |
| Net income | 780M 112M 95.22M 88.29M 82.87M 154M 10.24B 164M 1.01B 400M 4.85B 420M 411M 17.73B | 1.19B 170M 145M 134M 126M 234M 15.56B 249M 1.53B 607M 7.37B 638M 624M 26.93B |
| Net Debt | - | - |
More financial data
* Estimated data
Employees
1,274
Sector
Pharmaceuticals
Calendar
Mar. 11
- Q4 2025 Earnings Release
| Date | Price | Change | Volume |
|---|---|---|---|
| 26-01-22 | 20.40 ¥ | -0.78% | 3,736,395 |
| 26-01-21 | 20.56 ¥ | +3.58% | 7,223,856 |
| 26-01-20 | 19.85 ¥ | -0.30% | 2,821,044 |
| 26-01-19 | 19.91 ¥ | -1.14% | 2,752,830 |
| 26-01-16 | 20.14 ¥ | -0.30% | 3,035,051 |
End-of-day quote Shanghai S.E., January 21, 2026
More quotes
Sell
Buy
Mean consensus
BUY
Number of Analysts
2
Last Close Price
20.40CNY
Average target price
32.00CNY
Spread / Average Target
+56.86%
Quarterly revenue - Rate of surprise
- Stock Market
- Equities
- 688276 Stock
Select your edition
All financial news and data tailored to specific country editions
